This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
储存条件
4 °C,-20 °C
储存方法
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Abraham, Knapp, Cheng, Snyder, Mittal, Bangari, Kinch, Wu, Dhariwal, Mohammed: "Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder." in: Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 12, Issue 2, pp. 353-60, (2006) (PubMed).
Landen, Kinch, Sood: "EphA2 as a target for ovarian cancer therapy." in: Expert opinion on therapeutic targets, Vol. 9, Issue 6, pp. 1179-87, (2005) (PubMed).
EPH receptor A2 (EphA2), with 976-amino acid protein (about 107 kDa), belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphA10, EphB1, EphB2, EphB3, EphB4 and EphB6 are Eph family receptors for Ephrin family ligands. In normal cells, EphA2 negatively regulates cell growth and invasiveness. EphA2 is overexpressed by many human cancers, and is often associated with poor prognostic features. The clinical significance of the expression of EphA2 was observed in breast, prostate, colon, skin, cervical, ovarian, and lung cancers.EphA2 may serve as a novel target for bladder cancer, colonic adenocarcinoma and ovarian cancer therapy.